United Therapeutics UTHR Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 352.1%-2.4pp | 354.5%-1.3pp | 355.8%-0.3pp | 356.2%+0.1pp | 356%+0.1pp | |
| Operating margin | 187%-1.6pp | 188.6%-1.0pp | 189.5%+1.3pp | 188.2%-1.2pp | 189.4%-3.4pp | |
| Net margin | 163.6%+0.2pp | 163.4%+0.4pp | 163%+0.3pp | 162.6%-0.5pp | 163.1%-1.6pp | |
| Returns | ||||||
| Return on equity | 79.3%+0.3pp | 79%+0.5pp | 78.5%+1.2pp | 77.3%0.0pp | 77.2%-0.1pp | |
| Efficiency | ||||||
| Asset turnover | 1.7×0.0× | 1.7×0.0× | 1.7×0.0× | 1.6×0.0× | 1.6×0.0× | |
| Liquidity | ||||||
| Current ratio | 25.1×-0.7× | 25.7×+1.4× | 24.4×+1.8× | 22.5×+2.9× | 19.6×+1.7× | |
| Per Share | ||||||
| Book value per share | $561.02-2.6% | $576.06+2.7% | $560.78+2.4% | $547.51+5.5% | $518.92+6.7% | |
| Valuation | ||||||
| Market capitalization | $79.01B+18.2% | $66.86B+8.5% | $61.63B+5.2% | $58.59B-3.1% | $60.48B+5.3% | |
| Price / earnings | 61.3×+8.8× | 52.6×+2.5× | 50.1×+0.6× | 49.5×-3.5× | 52.9×+1.2× | |
| Price / sales | 25.1×+3.6× | 21.5×+1.1× | 20.4×+0.3× | 20.1×-1.5× | 21.6×+0.3× | |
| Price / book | 12.1×+2.4× | 9.7×+0.5× | 9.2×+0.3× | 8.9×-0.8× | 9.7×0.0× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are United Therapeutics's profit margins?
- United Therapeutics (UTHR) runs a 86.6% gross margin and a 45.3% operating margin, with a 40.6% net margin.
- Where do United Therapeutics's ratios come from?
- Every ratio is computed from United Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
